Antiangiogenic therapy using nanotechnological-based delivery system.
Of the many approaches for the treatment of cancer, angiogenesis and the additional promotion of apoptosis in cancer stem cells by using combinatorial therapy is usually the most recommended. There has been increased interest in the use of antiapoptotic and antiangiogenic biomolecules, such as antiangiogenic microRNA, small interfering RNA, inhibitor of apoptosis protein-binding peptides and Von Hippel-Lindau tumor suppressors, as well as targeting ligands, such as aptamers. Therefore, it is tempting to suggest that such molecules could be used for anticancer therapy. As we review here, such exploitation can be achieved by using nanotechnology and RNA-carrying cationic cell-penetrating peptides, for better protection from the enzymatic digestion and enhanced cellular internalization of these biomolecules.
Laboratory of Immunology and Molecular Biomedical Research (LIMBR), Centre for Biotechnology and Interdisciplinary Biosciences (BioDeakin), Institute for Technology Research and Innovation (ITRI), Deakin University, Waurn Ponds, VIC 3217, Australia. jagat.kanwar@deakin.edu.au
Jagat R
JR
Kanwar
Ganesh
G
Mahidhara
Rupinder K
RK
Kanwar
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D016503:Drug Delivery Systems; D006801:Humans; D053758:Nanoparticles; D036103:Nanotechnology / Q000379:methods; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D014411:Neoplastic Stem Cells; D012313:RNA / Q000008:administration & dosage
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D012313:RNA